NDC 72934-7039

CICLOPIROX OLAMINE 0.77% / CLOBETASOL PROPIONATE 0.05% / SALICYLIC ACID 3%.

Ciclopirox Olamine 0.77% / Clobetasol Propionate 0.05% / Salicylic Acid 3%.

CICLOPIROX OLAMINE 0.77% / CLOBETASOL PROPIONATE 0.05% / SALICYLIC ACID 3%. is a Topical Shampoo in the Human Prescription Drug category. It is labeled and distributed by Sincerus Florida, Llc. The primary component is Salicylic Acid; Ciclopirox Olamine; Clobetasol Propionate.

Product ID72934-7039_89048552-4502-fcc6-e053-2995a90ace5b
NDC72934-7039
Product TypeHuman Prescription Drug
Proprietary NameCICLOPIROX OLAMINE 0.77% / CLOBETASOL PROPIONATE 0.05% / SALICYLIC ACID 3%.
Generic NameCiclopirox Olamine 0.77% / Clobetasol Propionate 0.05% / Salicylic Acid 3%.
Dosage FormShampoo
Route of AdministrationTOPICAL
Marketing Start Date2019-05-17
Marketing CategoryUNAPPROVED DRUG OTHER / UNAPPROVED DRUG OTHER
Labeler NameSincerus Florida, LLC
Substance NameSALICYLIC ACID; CICLOPIROX OLAMINE; CLOBETASOL PROPIONATE
Active Ingredient Strength3 g/100g; g/100g; g/100g
Pharm ClassesDecreased DNA Replication [PE],Decreased Protein Synthesis [PE],Decreased RNA Replication [PE],Protein Synthesis Inhibitors [MoA],Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 72934-7039-6

120 g in 1 BOTTLE, PLASTIC (72934-7039-6)
Marketing Start Date2019-05-17
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 72934-7039-6 [72934703906]

CICLOPIROX OLAMINE 0.77% / CLOBETASOL PROPIONATE 0.05% / SALICYLIC ACID 3%. SHAMPOO
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitGM
Marketing Start Date2019-05-17

Drug Details

Active Ingredients

IngredientStrength
SALICYLIC ACID3 g/100g

OpenFDA Data

SPL SET ID:89048552-4501-fcc6-e053-2995a90ace5b
Manufacturer
UNII

Pharmacological Class

  • Decreased DNA Replication [PE]
  • Decreased Protein Synthesis [PE]
  • Decreased RNA Replication [PE]
  • Protein Synthesis Inhibitors [MoA]
  • Corticosteroid [EPC]
  • Corticosteroid Hormone Receptor Agonists [MoA]
  • Decreased DNA Replication [PE]
  • Decreased Protein Synthesis [PE]
  • Decreased RNA Replication [PE]
  • Protein Synthesis Inhibitors [MoA]
  • Corticosteroid [EPC]
  • Corticosteroid Hormone Receptor Agonists [MoA]

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.